First-Line ART Regimen With Dolutegravir Plus Lamivudine Safe, Efficacious In Treatment-Naive Patients With HIV, Study Finds

Infectious Disease Advisor (5/19, Nye) reports a study found that “dolutegravir (DTG) plus lamivudine (3TC) has high efficacy as first-line antiretroviral therapy (ART) in treatment-naive patients with HIV infection, including for those with very high baseline viral load.” Researchers observed that the results of the single-arm STAT study “demonstrated that the fixed-dose combination DTG/3TC had high efficacy and a favorable safety profile when administered as first-line ART in a similar population.” They found the “increase in CD4 T-cell count was similar across patients in all viral load groups...over the study period.” The study was published in Open Forum Infectious Diseases.